APIA, Samoa, Dec. 26, 2025 /PRNewswire/ — Phemex, a user-first crypto exchange, has announced a major upgrade to its Retail Price Improvement (RPI) order system. By deepening strategic ties with top-tier institutional liquidity partners, the enhanced RPI ecosystem now delivers market-leading depth that significantly outperforms industry benchmarks.
Latest data from a comprehensive market audit conducted in late 2025 reveals that the RPI upgrade has triggered a massive surge in liquidity across Phemex’s core assets. Based on internal comparative research of public order book depth (±0.1% from mid-price) relative to top-tier exchange averages:
RPI orders are specifically engineered as Maker orders for retail customers (non-API manual traders). This upgrade ensures a much denser order book and more aggressive pricing, narrowing spreads and providing “price improvement” that often exceeds the visible order book.
By ensuring that RPI orders interact exclusively with the retail maker liquidity — effectively bypassing high-frequency API algorithms — Phemex’s upgraded RPI has allowed the platform to maintain a competitive edge in liquidity across more than 210 trading pairs. This reinforces Phemex’s commitment to providing a transparent and high-performance environment where retail users can trade with the same precision and execution quality as institutional giants.
About Phemex
Founded in 2019, Phemex is a user-first crypto exchange trusted by over 10 million traders worldwide. The platform offers spot and derivatives trading, copy trading, and wealth management products designed to prioritize user experience, transparency, and innovation. With a forward-thinking approach and a commitment to user empowerment, Phemex delivers reliable tools, inclusive access, and evolving opportunities for traders at every level to grow and succeed.
For more information, please visit: https://phemex.com/
Logo – https://mma.prnewswire.com/media/2819516/Phemex_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/phemex-upgrades-rpi-ecosystem-setting-new-liquidity-benchmarks-across-210-pairs-302649630.html
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…
June 05, 2026 19:30 ET | Source: Oban BioPharma, Inc. STAMFORD, Conn., June 05, 2026…
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and…